Can you please introduce yourself and your role at LifeArc? As part of my Biochemistry degree at University of Leeds, I completed an industry placement at LifeArc. This was my first introduction to ...

Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues, and ...

Proxygen’s second lead candidate, CDK12, is a brain-penetrant glue degrader program designed to inactivate the transcriptional kinase CDK12, a target implicated in aggressive HER2-driven cancers and ...

Protein-degrader structure and function have been captured in unprecedented detail. Protein degraders are recognized as an exciting avenue for drug discovery and development, providing targeted ...

Targeted protein degradation (TPD) approaches including PROTAC and molecular glue have revolutionized drug discovery. However, in part due to complication of the ubiquitination and related ...

A specific cellular mechanism regulates the protein balance of plants, thereby influencing how they respond to environmental ...

Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that data from its Phase ...

Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments. Based on a cell’s natural mechanism for eliminating diseased proteins, this therapy can combat hard-to-treat ...

Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programsPresentations reinforce potential of degraders ...

Effective and efficient protein purification processes are essential in drug discovery and development. Affinity fusion tags ...